Background
Methods
Study population
Definition of major comorbidities, cardiovascular events and outcomes
Statistical analysis
Results
Clinical characteristics of COPD patients
Characteristics | All | LAMA | LABA | LAMA + LABA | LABA + ICS | Triple therapy |
---|---|---|---|---|---|---|
Numbers, (%) | 1565 | 760 (48.6) | 161 (10.3) | 405 (25.9) | 556 (35.5) | 211 (13.5) |
Age (years), median (range) | 73 (40–98) | 73 (42–96) | 75 (43–94) | 73 (40–93) | 71.5 (40–98) | 77 (42–97) |
Gender | ||||||
Male | 1224 (78.2) | 643 (84.6) | 137 (85.1) | 360 (88.9) | 362 (65.1) | 176 (83.4) |
Female | 341 (21.8) | 117 (15.4) | 24 (14.9) | 45 (11.1) | 194 (34.9) | 35 (16.6) |
Body mass index, median (range) | 24.2 (11.0–47.5) | 24.1 (11.2–46.2) | 23.5 (11.2–45.5) | 23.8 (12.0–44.1) | 24.5 (12.0–47.5) | 23.2 (12.8–44.2) |
CAT score, N(%) | 424 (27.1) | 240 (31.6) | 67 (41.6) | 173 (42.7) | 121 (21.8) | 73 (34.6) |
Mean (SD) | 7.74 (6.35) | 7.44 (6.39) | 9.67(8.02) | 9.41 (7.21) | 7.06 (6.12) | 8.85 (6.04) |
History of exacerbations in the previous year | ||||||
0 | 1127 (72.0) | 546 (71.8) | 100 (62.1) | 251 (62.0) | 406 (73.0) | 124 (58.8) |
1 | 316 (20.2) | 150 (19.7) | 37 (23.0) | 104 (25.7) | 111 (20.0) | 58 (27.5) |
> 2 | 122 (7.8) | 64 (8.4) | 24 (14.9) | 50 (12.3) | 39 (7.0) | 29 (13.7) |
Smoking Status | ||||||
Current | 266 (17.0) | 137 (18.0) | 30 (18.6) | 81 (20.0) | 80 (14.4) | 37 (17.5) |
Ex-smoker | 530 (33.9) | 284 (37.4) | 71 (44.1) | 186 (45.9) | 143 (25.7) | 90 (42.7) |
Never smoker | 769 (49.1) | 339 (44.6) | 60 (37.3) | 138 (34.1) | 333 (59.9) | 84 (39.8) |
Spirometry (FEV1, %) | ||||||
≥ 80 | 505 (32.3) | 315 (41.4) | 47 (29.2) | 75 (18.5) | 152 (27.3) | 36 (17.1) |
50–79 | 604 (38.6) | 257 (33.8) | 53 (32.9) | 159 (39.3) | 249 (44.8) | 55 (26.1) |
30–49 | 360 (23.0) | 146 (19.2) | 45 (28.0) | 132 (32.6) | 127 (22.8) | 80 (37.9) |
≤ 29 | 96 (6.1) | 42 (5.5) | 16 (9.9) | 39 (9.6) | 28 (5.0) | 40 (19.0) |
Underlying Comorbidities | ||||||
Metabolic disease | ||||||
Diabetes mellitus | 282 (18.0) | 145 (19.1) | 31 (19.3) | 72 (17.8) | 95 (17.1) | 43 (20.4) |
Hyperlipidemia | 131 (8.4) | 77 (10.1) | 11 (6.8) | 41 (10.1) | 51 (9.2) | 12 (5.7) |
Cardiovascular disease | ||||||
Hypertension | 548 (35.0) | 260 (34.2) | 61 (37.9) | 144 (35.6) | 196 (35.5) | 93 (44.1) |
Coronary artery disease | 149 (9.5) | 74 (9.7) | 19 (11.8) | 47 (11.6) | 59 (10.6) | 21 (10.0) |
Heart failure | 93 (5.9) | 46 (6.0) | 12 (7.5) | 25 (6.2) | 34 (6.1) | 15 (7.1) |
Arrhythmia | 50 (3.2) | 24 (3.2) | 7 (4.3) | 12 (3.0) | 18 (3.2) | 8 (3.8) |
Chronic kidney disease | 360/1393 (25.8) | 178/690 (25.8) | 39/152 (25.7) | 102/370 (27.6) | 114/479 (23.8) | 55/197 (27.9) |
Malignancy | ||||||
Lung cancer | 38 (2.4) | 22 (2.9) | 7 (4.3) | 13 (3.2) | 11 (2.0) | 2 (0.9) |
Other cancer | 27 (1.7) | 8 (1.1) | 2 (1.2) | 6 (1.5) | 9 (1.6) | 6 (2.8) |
Major comorbidities lead to adverse cardiovascular events
Clinical characteristics | Cardiovascular effects (n = 124) | Cerebral vascular stroke (n = 17) | ||
---|---|---|---|---|
Odds ratio | P value | Odds ratio | P value | |
Male | 2.76 | 0.001* | 0.90 | 0.861 |
Age ≥ 65 y/o | 1.52 | 0.082 | 2.41 | 0.230 |
Current or ever smoker | 1.59 | 0.015* | 0.52 | 0.197 |
Body mass index (BMI) | ||||
BMI < 18.5 | 0.46 | 0.089 | 2.50 | 0.141 |
BMI ≥ 27 | 1.81 | 0.002* | 0.60 | 0.582 |
FEV1 < 50% | 1.54 | 0.025* | 0.75 | 0.609 |
History of exacerbations in the previous year | ||||
1 | 2.17 | < 0.001** | 1.42 | 3.31 |
≥ 2 | 3.59 | < 0.001** | 2.13 | 6.08 |
Major Comorbidities | ||||
Diabetes mellitus | 1.90 | 0.002* | 0.28 | 0.190 |
Hyperlipidemia | 2.96 | < 0.001** | 1.45 | 0.619 |
Cardiovascular disease | 7.76 | < 0.001** | 6.50 | 0.001* |
CKD (Ccr < 60 ml/min) | 2.86 | < 0.001** | 1.20 | 0.735 |
Bronchodilators and treatment duration | ||||
LAMA | 1.75 | 0.003* | 1.52 | 0.395 |
≥ 90 days | 0.85 | 0.474 | 0.99 | 0.990 |
≥ 180 days | 0.96 | 0.866 | 0.42 | 0.134 |
≥ 360 days | 1.07 | 0.762 | 0.32 | 0.120 |
LABA | 1.12 | 0.702 | N/A | 0.160 |
≥ 90 days | 1.26 | 0.518 | N/A | 0.297 |
≥ 180 days | 1.54 | 0.295 | N/A | 0.404 |
≥ 360 days | 1.46 | 0.536 | N/A | 0.583 |
LAMA/LABA | 1.46 | 0.057 | 1.57 | 0.373 |
≥ 90 days | 1.01 | 0.974 | 1.96 | 0.200 |
≥ 180 days | 1.07 | 0.788 | 1.27 | 0.711 |
≥ 360 days | 1.12 | 0.727 | 2.48 | 0.144 |
ICS/LABA | 0.64 | 0.031* | 0.39 | 0.121 |
≥ 90 days | 0.87 | 0.504 | 0.59 | 0.352 |
≥ 180 days | 0.99 | 0.953 | 0.74 | 0.601 |
≥ 360 days | 1.05 | 0.839 | 1.00 | 0.994 |
Triple therapy | 0.95 | 0.844 | 1.38 | 0.613 |
≥ 90 days | 1.02 | 0.951 | 0.59 | 0.607 |
≥ 180 days | 0.99 | 0.983 | 0.71 | 0.735 |
≥ 360 days | 0.79 | 0.588 | N/A | 0.297 |
Cardiovascular events, n (%) | Odds ratio | p | Strokes, n (%) | Odds ratio | p | |
---|---|---|---|---|---|---|
LAMA | ||||||
With CVD (n = 317) | 60 (18.9) | 6.23 | < 0.001** | 9 (2.8) | 12.92 | 0.002* |
Without (n = 443) | 16 (3.6) | 1 (0.2) | ||||
With CKD (n = 178) | 36 (20.2) | 3.08 | < 0.001** | 2 (1.1) | 0.72 | 0.673 |
Without (n = 512) | 39 (7.6) | 8 (1.6) | ||||
LABA | ||||||
With CVD (n = 78) | 13 (16.7) | 16.4 | 0.001* | 0 (0.0) | ||
Without (n = 83) | 1 (1.2) | 0 (0.0) | ||||
With CKD (n = 39) | 7 (17.9) | 3.34 | 0.027* | 0 (0.0) | ||
Without (n = 114) | 7 (6.1) | 0 (0.0) | ||||
LABA/LAMA | ||||||
With CVD (n = 183) | 33 (18.0) | 5.89 | < 0.001** | 4 (2.2) | 2.46 | 0.287 |
Without (n = 222) | 8 (3.6) | 2 (0.9) | ||||
With CKD (n = 102) | 23 (22.5) | 4.30 | < 0.001** | 3 (2.9) | 2.68 | 0.215 |
Without (n = 268) | 17 (6.3) | 3 (1.1) | ||||
ICS/LABA | ||||||
With CVD (n = 236) | 30 (12.7) | 15.39 | < 0.001** | 3 (1.3) | N/A | 0.043* |
Without (n = 320) | 3 (0.9) | 0 (0.0) | ||||
With CKD (n = 114) | 17 (14.9) | 4.09 | < 0.001** | 0 (0.0) | N/A | 0.332 |
Without (n = 365) | 15 (4.1) | 3 (0.8) | ||||
Triple therapy | ||||||
With CVD (n = 110) | 13 (11.8) | 4.38 | 0.015* | 3 (2.7) | N/A | 0.095 |
Without (n = 101) | 3 (3.0) | 0 (0.0) | ||||
With CKD (n = 55) | 8 (14.5) | 2.85 | 0.040* | 1 (1.8) | 1.30 | 0.833 |
Without (n = 142) | 8 (5.6) | 2 (1.4) |
Chronic kidney disease predicts risk of mortality in COPD patients with multimorbidity using long- acting bronchodilators
Mortality causes | N (%) |
---|---|
Total | 87 |
Cardiovascular-related | 19 |
Cardiac arrest | 7 (8.0) |
Acute decompensated heart failure | 6 (6.9) |
Acute myocardial infarction | 3 (3.4) |
Cerebral vascular stroke | 3 (3.4) |
Respiratory-related | 64 |
Pneumonia with respiratory failure | 38 (43.7) |
COPD acute exacerbation | 26 (29.9) |
Sepsis | 4 |
OR | 95% CI | P value | ||
---|---|---|---|---|
(a) All-causes mortality | ||||
Male | 0.79 | 0.37 | 1.67 | 0.532 |
Age > 65 | 1.52 | 0.70 | 3.28 | 0.292 |
Smoking | 0.87 | 0.50 | 1.53 | 0.634 |
BMI > 27 | 0.53 | 0.26 | 1.07 | 0.077 |
FEV1 < 50% | 1.66 | 0.96 | 2.88 | 0.070 |
DM | 0.70 | 0.36 | 1.37 | 0.297 |
Hyperlipidemia | 0.58 | 0.22 | 1.58 | 0.289 |
CVD | 1.73 | 1.00 | 2.97 | 0.048* |
CKD | 2.45 | 1.45 | 4.14 | 0.001* |
LAMA | 1.00 | 0.59 | 1.70 | 0.994 |
ICS/LABA | 0.32 | 0.17 | 0.63 | 0.001* |
History of exacerbations in the previous year | ||||
1 | 1.43 | 0.78 | 2.63 | 0.243 |
> 2 | 4.33 | 2.20 | 8.50 | < 0.001** |
Malignancy | ||||
Lung cancer | 27.24 | 12.16 | 61.04 | < 0.001** |
Other cancer | 19.39 | 7.85 | 47.87 | < 0.001** |
(b) Respiratory-related mortality | ||||
Male | 0.83 | 0.34 | 1.98 | 0.667 |
Age > 65 | 1.19 | 0.52 | 2.70 | 0.681 |
Smoking | 0.80 | 0.42 | 1.52 | 0.491 |
BMI > 27 | 0.48 | 0.20 | 1.15 | 0.100 |
FEV1 < 50% | 1.82 | 0.97 | 3.41 | 0.060 |
DM | 0.75 | 0.35 | 1.62 | 0.466 |
Hyperlipidemia | 0.53 | 0.16 | 1.73 | 0.295 |
CVD | 1.64 | 0.88 | 3.06 | 0.116 |
CKD | 1.52 | 0.82 | 2.82 | 0.185 |
LAMA | 1.11 | 0.61 | 2.03 | 0.739 |
ICS/LABA | 0.40 | 0.19 | 0.83 | 0.014* |
History of exacerbations in the previous year | ||||
1 | 2.03 | 1.03 | 4.00 | 0.041* |
> 2 | 4.61 | 2.14 | 9.93 | < 0.001** |
Malignancy | ||||
Lung cancer | 35.79 | 15.65 | 81.82 | < 0.001** |
Other cancer | 11.72 | 4.27 | 32.17 | < 0.001** |
(c) Cardiovascular-related mortality | ||||
Male | 0.79 | 0.19 | 3.33 | 0.745 |
Age > 65 | 3.06 | 0.38 | 24.76 | 0.294 |
Smoking | 1.11 | 0.39 | 3.14 | 0.849 |
BMI > 27 | 0.85 | 0.26 | 2.79 | 0.793 |
FEV1 < 50% | 1.40 | 0.49 | 4.00 | 0.527 |
DM | 0.49 | 0.14 | 1.71 | 0.265 |
Hyperlipidemia | 1.14 | 0.23 | 5.70 | 0.869 |
CVD | 2.99 | 0.98 | 9.10 | 0.053 |
CKD | 4.87 | 1.75 | 13.55 | 0.002* |
LAMA | 0.93 | 0.34 | 2.56 | 0.889 |
ICS/LABA | 0.33 | 0.09 | 1.25 | 0.103 |
History of exacerbations in the previous year | ||||
1 | 0.60 | 0.16 | 2.26 | 0.451 |
> 2 | 2.01 | 0.57 | 7.12 | 0.277 |
Malignancy | ||||
Lung cancer | 1.43 | 0.17 | 12.34 | 0.742 |
Other cancer | 10.33 | 2.42 | 44.03 | 0.002* |